Christopher James Agrusa

Christopher Agrusa practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Christopher Agrusa's NPI, 1841432945, was assigned on April 3, 2009. Christopher Agrusa graduated from New York University School of Medicine in 2009. Christopher Agrusa holds New York license 265037.

Christopher Agrusa's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Christopher Agrusa's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Christopher Agrusa to 2 more clinical labs, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Christopher Agrusa practices, 4 sites in all. Vendor and product names are available with a free account.

Vascular surgery is Christopher Agrusa's primary specialty in the NPI Registry, under taxonomy code 2086S0129X. Christopher Agrusa is board certified in surgery by the American Board of Surgery. Christopher Agrusa is licensed in New York.

Dmand AI lists amputation, blood vessel access for dialysis, chronic skin ulcer, circulatory problems in extremities, deep vein thrombosis (DVT), leg revascularization, lymphedema and peripheral vascular disease among the conditions Christopher Agrusa treats.

CMS data shows 908 Medicare services from Christopher Agrusa across 18 procedure codes in 2024, for 385 Medicare patients. Medicare paid $114,662 for them.

CMS counts 385 Medicare patients who saw Christopher Agrusa in 2024. The largest group is 65 to 74, with 131 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 3.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Christopher Agrusa's median patient age at 62, with 48% women.

In 2024, Christopher Agrusa wrote 27 Medicare Part D claims for 11 patients. 85% of them were for generic drugs. They cover 2 drugs, with $198 in total drug cost. In 2019, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Christopher Agrusa for performance year 2024, reported through an alternative payment model (APM). Christopher Agrusa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Christopher Agrusa as offering telehealth. CMS counts 33 procedures of leg revascularization (restoring blood flow) by Christopher Agrusa, more than 90% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 13 papers to Christopher Agrusa, published from 2019 to 2024. 2023 was the busiest year, with 3. The most frequent topics are Blood Vessel Prosthesis Implantation, Endovascular Procedures and Aortic Aneurysm, Thoracic. Christopher Agrusa has published most often in Ann Vasc Surg. Christopher Agrusa's most frequent co-authors are Peter H. Connolly, MD, Sharif Ellozy, MD and Darren B. Schneider, MD.

CMS Open Payments shows 202 general payments to Christopher Agrusa from 34 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 85% of the total. W. L. Gore & Associates, Inc. paid the most, $4,831.

Christopher Agrusa graduated from New York University School of Medicine in 2009.

Christopher Agrusa is in network with 15 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.